Delving into the Latest Updates on CLX-0901 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

CLX 0901

Target

Tyrosine kinase

Mechanism

Tyrosine kinase inhibitors, Insulin sensitizers

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Diabetes Mellitus, Type 2

Originator Organization

Theracos, Inc.

Active Organization-

Inactive Organization

PHARMARESEARCH BIO Co., Ltd.

Theracos, Inc.

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Calyx Therapeutics is developing the insulin sensitizer, CLX-0901, as an antidiabetic agent. CLX-0901 is the synthetic analog of CLX-0900 which was originally isolated from a plant source. Phase I and toxicological studies indicate that the compound is safe and well tolerated [363764]. As of March 2001, phase II studies had commenced [402737]. Other antidiabetics being investigated by Calyx include CLX-0301, CLX-0921, CLX-0940, CLX-0100 and CLX-0101 [376032].

01 Aug 2000·IDrugs : the investigational drugs journal

Obesity: Adipogenesis and Insulin Resistance.

Article

Author: Sethi, J K

This meeting focused on the recent developments in the fields of adipogensis and insulin resistance. In particular, the molecular mechanisms presented were those that are likely to be relevant as drug discovery targets for the treatment of obesity and diabetes. New compounds included the LIFR antagonist, hLIF05, and LG- 100641, a selective antagonist of PPARgamma but with insulin sensitizing actions in adipocytes. The small insulin sensitizers discussed were CLX-0901, isolated from plant extracts and currently in phase I clinical trials, TLK-17411, a small synthetic compound and S-15261, which increases insulin sensitivity.

100 Deals associated with CLX-0901

Login to view more data